* agilon health inc AGL.N AGL is expected to show a rise
in
quarterly revenue when it reports results on November 2.
* The Austin Texas-based company is expected to report a
63.7% increase in revenue to $1.138 billion from $694.86 million
a year ago, according to the mean estimate from 16 analysts,
based on LSEG data. The company's guidance on August 3 2023, for
the period ended September 30, was for revenue between $1.13
billion and $1.14 billion.
* Refinitiv's mean analyst estimate for agilon health inc
is for
a loss of 6 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 14 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for agilon
health inc
is $28, above its last closing price of $18.00.
The company's guidance on August 3 2023 for the period ended
September 30 was for Earnings before Interest, Taxes,
Depreciation and Amortization of between 1.13 billion and 0
(USD).
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Jun. 30 2023 -0.03 -0.03 -0.04 Missed -57.5
Mar. 31 2023 0.02 0.02 0.04 Beat 83.3
Dec. 31 2022 -0.07 -0.09 -0.14 Missed -62.8
Sep. 30 2022 -0.06 -0.05 -0.07 Missed -40
Jun. -0.02 -0.02 -0.05 Missed -177.8
30 2022
Mar. 31 2022 0.00 0.00 0.00 Met -100
Dec. 31 2021 -0.14 -0.11 -0.14 Missed -27.3
Sep. 30 2021 -0.10 -0.10 -0.09 Beat 6.9
This summary was machine generated November 1 at 02:07 GMT. All
figures in US dollars unless otherwise stated